Panacea Biotec Shares Soar 10% on Major Dengue Vaccine Trial Milestone

• Panacea Biotec shares surged up to 10% on BSE, reaching Rs 422.30, with market cap nearing Rs 2500 crore.
• The surge followed the completion of enrollment for Phase III clinical trials of its dengue vaccine candidate, 'Dengioall'.
• 10,335 participants enrolled in the late-stage trial will be monitored for two years to assess efficacy and immunogenicity.
• 'Dengioall' is a tetravalent, single-dose vaccine using attenuated strains, expected to be India's first indigenous dengue vaccine.
• The vaccine, under development since 2008, could be launched by 2027; stock rose 117% in 2 years.

Why It Matters: Panacea Biotec stock jumped on positive Phase III trial news for its indigenous single-dose dengue vaccine.